Skip to main content
Erschienen in: Journal of Endocrinological Investigation 10/2022

01.10.2022 | Review

Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence

verfasst von: A. Jafarzadeh, M. Nemati, S. Jafarzadeh, P. Nozari, S. M. J. Mortazavi

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The safety and efficacy of the several types of COVID-19 vaccines, including mRNA-based, viral vector-based, and inactivated vaccines, have been approved by WHO. The vaccines can confer protection against severe SARS-CoV-2 infection through induction of the anti-spike protein neutralizing antibodies. However, SARS-CoV-2 vaccines have been associated with very rare complications, such as thyroid disorders. This review was conducted to highlight main features of thyroid abnormalities following COVID-19 vaccination.

Methods

A comprehensive search within electronic databases was performed to collect reports of thyroid disorders after vaccination with COVID-19 vaccines.

Results

Among 83 reported cases including in this review, the most cases of thyroid abnormalities were observed after vaccination with mRNA-based vaccines (68.7%), followed by viral vector vaccines (15.7%) and 14.5% cases following inactivated vaccines. Subacute thyroiditis (SAT) was the most common COVID-19 vaccination-related thyroid disease, accounting for 60.2% of all cases, followed by Graves' disease (GD) with 25.3%. Moreover, some cases with focal painful thyroiditis (3.6%), silent thyroiditis (3.6%), concurrent GD and SAT (2.4%), thyroid eye disease (1.2%), overt hypothyroidism (1.2%), atypical subacute thyroiditis (1.2%), and painless thyroiditis with TPP (1.2%) were also reported. Overall, in 58.0% of SAT cases and in 61.9% of GD cases, the onset of the symptoms occurred following the first vaccine dose with a median of 10.0 days (ranged: 3–21 days) and 10.0 days (ranged: 1–60 days) after vaccination, respectively. Moreover, 40.0% of SAT patients and 38.1% of GD patients developed the symptoms after the second dose with a median of 10.5 days (ranged: 0.5–37 days) and 14.0 days (ranged: 2–35 days) after vaccination, respectively.

Conclusion

Fortunately, almost all cases with COVID-19 vaccination-associated thyroid dysfunctions had a favorable outcome following therapy. The benefits of COVID-19 vaccinations in terms of terminating the pandemic and/or reducing mortality rates can exceed any risk of infrequent complications such as a transient thyroid malfunction.
Literatur
54.
Zurück zum Zitat Mehraji Z, Farazmand A, Esteghamati A, Noshad S, Sadr M, Amirzargar S, Yekaninejad MS, Amirzargar A (2017) Association of human leukocyte antigens class I and II with Graves’ Disease in Iranian population. Iran J Immunol 14(3):223–230PubMed Mehraji Z, Farazmand A, Esteghamati A, Noshad S, Sadr M, Amirzargar S, Yekaninejad MS, Amirzargar A (2017) Association of human leukocyte antigens class I and II with Graves’ Disease in Iranian population. Iran J Immunol 14(3):223–230PubMed
64.
Zurück zum Zitat Sakiyama R (1986) Silent thyroiditis. J Fam Pract 23:367–369PubMed Sakiyama R (1986) Silent thyroiditis. J Fam Pract 23:367–369PubMed
72.
Zurück zum Zitat Hernán Martinez J, Corder E, Uzcategui M, Garcia M, Sostre S, Garcia A (2011) Subacute thyroiditis and dyserythropoesis after influenza vaccination suggesting immune dysregulation. Bol Asoc Med P R 103(2):48–52PubMed Hernán Martinez J, Corder E, Uzcategui M, Garcia M, Sostre S, Garcia A (2011) Subacute thyroiditis and dyserythropoesis after influenza vaccination suggesting immune dysregulation. Bol Asoc Med P R 103(2):48–52PubMed
78.
Zurück zum Zitat Toft J, Larsen S, Toft H (1998) Subacute thyroiditis after hepatitis B vaccination. Endocr J 45(1):135PubMed Toft J, Larsen S, Toft H (1998) Subacute thyroiditis after hepatitis B vaccination. Endocr J 45(1):135PubMed
96.
Zurück zum Zitat Davarpanah E, Jafarzadeh A, Nemati M, Bassagh A, Abasi MH, Khosravimashizi A, Kazemipoor N, Ghazizadeh M, Mirzaee M (2020) Circulating concentration of interleukin-37 in Helicobacter pylori-infected patients with peptic ulcer: Its association with IL-37 related gene polymorphisms and bacterial virulence factor CagA. Cytokine 126:154928. https://doi.org/10.1016/j.cyto.2019.154928CrossRefPubMed Davarpanah E, Jafarzadeh A, Nemati M, Bassagh A, Abasi MH, Khosravimashizi A, Kazemipoor N, Ghazizadeh M, Mirzaee M (2020) Circulating concentration of interleukin-37 in Helicobacter pylori-infected patients with peptic ulcer: Its association with IL-37 related gene polymorphisms and bacterial virulence factor CagA. Cytokine 126:154928. https://​doi.​org/​10.​1016/​j.​cyto.​2019.​154928CrossRefPubMed
97.
Metadaten
Titel
Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence
verfasst von
A. Jafarzadeh
M. Nemati
S. Jafarzadeh
P. Nozari
S. M. J. Mortazavi
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 10/2022
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-022-01786-7

Weitere Artikel der Ausgabe 10/2022

Journal of Endocrinological Investigation 10/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.